India Pharma Outlook Team | Tuesday, 17 November 2026
Targeted cancer treatment is gaining attention as pharmaceutical companies explore ways to make oncology therapies more selective.
Eli Lilly and biotechnology company Stipple Bio have entered a multi-target, multi-modality research collaboration and licensing agreement worth up to USD 5.9 billion.
Announced on November 16, 2026, the agreement will combine Stipple Bio's Pointillist Platform with Lilly's proprietary oncology technologies to identify tumour-specific targets and develop new cancer therapies.
The partnership gives Lilly exclusive worldwide rights to develop and commercialize products arising from the collaboration, expanding its efforts to strengthen its oncology pipeline.
Also Read: 5 Women Leaders Driving India's Pharma and Healthcare Innovation
Under the agreement, Stipple Bio will receive an undisclosed upfront payment and an equity investment from Lilly.
It is also eligible for up to USD 5.9 billion in milestone payments linked to research & development and commercialization, along with tiered royalties.
The agreement covers multiple targets and therapeutic modalities. The USD 5.9 billion represents potential milestone payments, not an immediate payment.
Stipple's Pointillist Platform identifies tumour-specific cell-surface epitopes, which are distinct regions of proteins that antibodies can recognize.
The technology aims to identify features present on cancer cells but absent from healthy cells. Stipple then develops antibody binders designed to recognize these targets.
This approach could help direct therapies towards cancer cells while reducing on-target, off-tumour toxicity, a challenge in which treatments also affect healthy cells.
However, its potential benefits will need to be established through clinical research.
Stipple's lead candidate, STP-100, is an antibody-drug conjugate (ADC) being developed for solid tumours, including pancreatic cancer. The company plans to begin Phase 1 clinical trials in early 2027.
In April 2026, Stipple announced an oversubscribed USD 100 million Series A financing to advance its lead candidate and expand its oncology pipeline.
The collaboration gives Lilly access to a platform focused on identifying tumour-specific targets. It could support the development of new targeted cancer treatment candidates across multiple therapeutic approaches.
For Stipple, the partnership provides access to Lilly's drug development and commercialization capabilities.
The success of the collaboration will depend on identifying viable targets and demonstrating the safety and effectiveness of resulting therapies in clinical trials.